AVIR

Atea Pharmaceuticals, Inc.

4.19 USD
-0.01 (-0.24%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Atea Pharmaceuticals, Inc. stock is up 9.11% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.65% of the previous 50 February’s closed higher than January. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 Feb 20:43 19 Jul, 2024 2.50 CALL 500 1428

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trials for dengue; AT-777, an NS5A inhibitor, and AT-281, a pharmaceutically acceptable salt.